Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free EXAS Stock Alerts $66.88 +1.64 (+2.51%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$65.11▼$66.9350-Day Range$56.27▼$66.8852-Week Range$56.05▼$100.77Volume1.71 million shsAverage Volume1.97 million shsMarket Capitalization$12.14 billionP/E RatioN/ADividend YieldN/APrice Target$99.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside48.5% Upside$99.31 Price TargetShort InterestHealthy3.59% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.93Based on 6 Articles This WeekInsider TradingSelling Shares$4.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.86) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.72 out of 5 starsMedical Sector84th out of 939 stocksMedical Laboratories Industry4th out of 19 stocks 3.4 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $99.31, Exact Sciences has a forecasted upside of 48.5% from its current price of $66.88.Amount of Analyst CoverageExact Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.59% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exact Sciences has recently decreased by 7.39%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 2.7 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Exact Sciences this week, compared to 7 articles on an average week.Search InterestOnly 28 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows22 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,096,879.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.86) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -58.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -58.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesMarch 1, 2024 | marketbeat.com3 Hot Stocks Bought by Members of Congress: Follow the MoneyThe STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let's be honest. The STOCK Act can't really stop Congresspeople from trading on insider knowledge; they're in a position to get it, which will influence investment decisions.March 1, 2024 | marketbeat.com3 Hot Stocks Bought by Members of Congress: Follow the Money (EXAS)Palo Alto Networks, Simon Property Group and JPMorgan Chase are the top three stocks bought by Members of Congress in February;March 28, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 28, 2024 | businesswire.comExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-CancerMarch 27, 2024 | finance.yahoo.comExact Sciences Named 2024 Gallup Exceptional Workplace Award WinnerMarch 26, 2024 | investorplace.com3 Growth Stocks to Buy at 52-Week Lows in MarchMarch 23, 2024 | nasdaq.comGuru Fundamental Report for EXAS - Benjamin GrahamMarch 21, 2024 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the companyMarch 28, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 20, 2024 | americanbankingnews.comInvestors Buy Large Volume of Exact Sciences Call Options (NASDAQ:EXAS)March 19, 2024 | benzinga.comExact Sciences Unusual Options ActivityMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)March 18, 2024 | finance.yahoo.comGuardant posts data for colon cancer blood test amid push from rivalsMarch 16, 2024 | finance.yahoo.comEXAS Apr 2024 50.000 putMarch 16, 2024 | finance.yahoo.comEXAS Jul 2024 42.500 putMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)March 13, 2024 | finance.yahoo.comCathie Wood Darling Exact Sciences Rises On Highly Anticipated Colon Cancer NewsMarch 13, 2024 | businesswire.comThe New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C StudyMarch 11, 2024 | fool.com2 Beaten-Down Cathie Wood Stocks With Massive PotentialMarch 7, 2024 | businesswire.comExact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon CancerMarch 5, 2024 | finance.yahoo.comExact Sciences Corp (EXAS) Director Daniel Levangie Sells 5,000 SharesMarch 4, 2024 | investorplace.comThe Top 3 Healthcare Stocks to Buy on Weakness in 2024March 4, 2024 | markets.businessinsider.com7 Stable Stocks to Buy for 100% Returns by 2025March 4, 2024 | investorplace.com7 Stable Stocks to Buy for 100% Returns by 2025March 3, 2024 | investorplace.comHidden Gems: 3 Market Underdogs to Buy at Rock-Bottom PricesFebruary 28, 2024 | businesswire.comExact Sciences Launches Riskguard™ Hereditary Cancer Test in the United StatesFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)See More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/27/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$99.31 High Stock Price Target$130.00 Low Stock Price Target$73.00 Potential Upside/Downside+48.5%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-8.17% Pretax Margin-8.07% Return on Equity-6.60% Return on Assets-3.20% Debt Debt-to-Equity Ratio0.74 Current Ratio2.32 Quick Ratio2.07 Sales & Book Value Annual Sales$2.50 billion Price / Sales4.86 Cash Flow$0.02 per share Price / Cash Flow3,743.83 Book Value$17.39 per share Price / Book3.85Miscellaneous Outstanding Shares181,530,000Free Float179,171,000Market Cap$12.14 billion OptionableOptionable Beta1.22 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsNateraNASDAQ:NTRAPRA Health SciencesNASDAQ:PRAHQuest DiagnosticsNYSE:DGXExelixisNASDAQ:EXELPPDNASDAQ:PPDView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 2,974 shares on 3/27/2024Ownership: 0.008%PNC Financial Services Group Inc.Bought 4,258 shares on 3/22/2024Ownership: 0.010%B. Riley Wealth Advisors Inc.Sold 525 shares on 3/15/2024Ownership: 0.002%Vanguard Group Inc.Bought 115,058 shares on 3/11/2024Ownership: 9.673%Wahed Invest LLCBought 227 shares on 3/11/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price target for 2024? 13 equities research analysts have issued 12 month target prices for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they predict the company's share price to reach $99.31 in the next year. This suggests a possible upside of 48.5% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2024? Exact Sciences' stock was trading at $73.98 on January 1st, 2024. Since then, EXAS stock has decreased by 9.6% and is now trading at $66.88. View the best growth stocks for 2024 here. Are investors shorting Exact Sciences? Exact Sciences saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 6,520,000 shares, a decline of 7.4% from the February 29th total of 7,040,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the short-interest ratio is currently 3.4 days. View Exact Sciences' Short Interest. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EXAS earnings forecast. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. The medical research company had revenue of $646.89 million for the quarter, compared to analysts' expectations of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative trailing twelve-month return on equity of 6.60%. The business's revenue was up 17.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.72) EPS. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Innovation ETF (ARKK), Principal Healthcare Innovators ETF (BTEC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT) and VanEck Biotech ETF (BBH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.71%), Vanguard Group Inc. (9.67%), Capital World Investors (4.13%), ARK Investment Management LLC (3.34%), Artisan Partners Limited Partnership (2.47%) and Baillie Gifford & Co. (2.08%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More This page (NASDAQ:EXAS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.